Potent N-(1,3-Thiazol-2-yl)pyridin-2-amine Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors with Excellent Pharmacokinetics and Low Affinity for the hERG Ion Channel
Journal of Medicinal Chemistry2004Vol. 47(25), pp. 6363–6372
Citations Over TimeTop 10% of 2004 papers
Mark T. Bilodeau, Adrienne E. Balitza, Timothy J. Koester, Peter J. Manley, Leonard D. Rodman, Carolyn Buser‐Doepner, Kathleen Coll, Christine Fernandes, W. Wayt Gibbs, David Heimbrook, William R. Huckle, Nancy E. Kohl, Joseph J. Lynch, Xianzhi Mao, Rosemary C. McFall, Debra A. McLoughlin, Cynthia Miller‐Stein, Keith Rickert, Laura Sepp‐Lorenzino, Jennifer M. Shipman, Raju Subramanian, Kenneth A. Thomas, Bradley K. Wong, Sean Yu, George D. Hartman
Abstract
A series of N-(1,3-thiazol-2-yl)pyridin-2-amine KDR kinase inhibitors have been developed that possess optimal properties. Compounds have been discovered that exhibit excellent in vivo potency. The particular challenges of overcoming hERG binding activity and QTc increases in vivo in addition to achieving good pharmacokinetics have been acomplished by discovering a unique class of amine substituents. These compounds have a favorable kinase selectivity profile that can be accentuated with appropriate substitution.
Related Papers
- → Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel(2005)39 cited
- → Identification and characterization of a novel genetic mutation with prolonged QT syndrome in an unexplained postoperative death(2013)10 cited
- → Pharmacological rescue of hERG currents carried out by G604S and wide type hERG co‐expression(2016)2 cited
- → Robust Deep Learning Architecture for hERG-related Cardiotoxicity Prediction on Small-Scale Dataset(2022)